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Abstract
Introduction: Hyper- and hypoglycemia are strongly associated with adverse outcomes in critical care.
Neurologically injured patients are a unique subgroup, where optimal glycemic targets may differ, such that the
findings of clinical trials involving heterogeneous critically ill patients may not apply.
Methods: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing
intensive insulin therapy with conventional glycemic control among patients with traumatic brain injury, ischemic
or hemorrhagic stroke, anoxic encephalopathy, central nervous system infections or spinal cord injury.
Results: Sixteen RCTs, involving 1248 neurocritical care patients, were included. Glycemic targets with intensive
insulin ranged from 70-140 mg/dl (3.9-7.8 mmol/L), while conventional protocols aimed to keep glucose levels
below 144-300 mg/dl (8.0-16.7 mmol/L). Tight glycemic control had no impact on mortality (RR 0.99; 95% CI 0.83-
1.17; p = 0.88), but did result in fewer unfavorable neurological outcomes (RR 0.91; 95% CI 0.84-1.00; p = 0.04).
However, improved outcomes were only observed when glucose levels in the conventional glycemic control
group were permitted to be relatively high [threshold for insulin administration > 200 mg/dl (> 11.1 mmol/L)], but
not with more intermediate glycemic targets [threshold for insulin administration 140-180 mg/dl (7.8-10.0 mmol/L)].
Hypoglycemia was far more common with intensive therapy (RR 3.10; 95% CI 1.54-6.23; p = 0.002), but there was a
large degree of heterogeneity in the results of individual trials (Q = 47.9; p<0.0001; I2 = 75%). Mortality was non-
significantly higher with intensive insulin in studies where the proportion of patients developing hypoglycemia was
large (> 33%) (RR 1.17; 95% CI 0.79-1.75; p = 0.44).
Conclusions: Intensive insulin therapy significantly increases the risk of hypoglycemia and does not influence
mortality among neurocritical care patients. Very loose glucose control is associated with worse neurological
recovery and should be avoided. These results suggest that intermediate glycemic goals may be most appropriate.
Introduction
A key paradigm in the care of patients with acute brain
and spinal cord injury is prevention of physiological
abnormalities that may contribute to secondary neurolo-
gical damage. Hyperglycemia is common in critically ill
patients, and has been associated with worsened out-
comes in the setting of traumatic brain injury (TBI) [1-9],
aneurysmal subarachnoid hemorrhage (SAH) [10-19],
spontaneous intracerebral hemorrhage (ICH) [20-26],
ischemic stroke [27-35] and anoxic brain injury [36-38].
The mechanisms whereby hyperglycemia could be harm-
ful are complex. Contributing factors may include free
radical formation and oxidative injury, activation of N-
methyl-D-aspartate receptors, raised intracellular cal-
cium, triggering of inflammatory and apoptotic pathways,
and alterations in lactate metabolism with reduced tissue
pH [39]. Despite these observations, it remains unclear
from human studies whether hyperglycemia is simply a
marker for a greater severity of neurological damage or
truly contributes to secondary injury in a causative fash-
ion. Hypoglycemia may also be deleterious, since neuro-
critical care patients are dependent on sufficient glucose
as an energy source for the central nervous system (CNS)
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[40,41]. Even moderate reductions in serum glucose can
result in pronounced neuroglycopenia [42-44].
Numerous randomized controlled trials (RCTs) have
assessed the efficacy and safety of intensive insulin ther-
apy and tight glycemic control regimens in the care of
critically ill patients. Despite initial enthusiasm based on
the results of single-center RCTs [45,46], more recent
multi-center RCTs have been unable to confirm any ben-
efit, and have even suggested harm [47-49]. Similarly,
meta-analyses have not demonstrated a reduction in
mortality with tight versus conventional glycemic control
[50-53].
Neurocritical care patients are a unique subgroup, in
which the association between hyperglycemia and
adverse outcomes in observational studies has been parti-
cularly strong. Although RCTs of tight glycemic control
in critically ill patients have focused largely on mortality
as the primary outcome, functional recovery is an espe-
cially meaningful endpoint in the neurologically injured.
Even if an intervention does not impact on mortality, it
may still be efficacious at improving functional and cog-
nitive outcomes among survivors. Thus, the findings of
RCTs involving heterogeneous populations of critically ill
patients may not necessarily apply.
Some meta-analyses have pooled results in specific sub-
groups of brain-injured patients [54-56]. However, results
from several RCTs were not included in these reviews. A
comprehensive overview of all clinical trials involving
neurocritical care patients has never been performed, and
the optimal approach to glycemic control remains largely
unknown. Therefore, we performed a systematic review
and meta-analysis to assess whether tight glycemic con-
trol reduces mortality and improves outcomes in neuro-
critical care patients. We also conducted stratified
analyses and meta-regression in an attempt to determine
whether particular clinical or study-design characteristics
influence the relationship between tight glycemic control
and patient outcomes.
Materials and methods
A written protocol, with a pre-specified analysis plan,
was developed prior to study initiation in accordance
with the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) statement [57].
Search strategy
Using the OVID interface, we conducted unrestricted
searches in MEDLINE, EMBASE, the Cochrane Central
Register of Controlled Trials (CENTRAL) and the
Cochrane Database of Systematic Reviews from their
inception date until the first week of November 2011. To
identify RCTs involving neurocritical care patients, the
Boolean operator AND was used to combine three search
concepts: intensive glycemic control, neurocritical care
(defined below) and clinical trials. These concepts were
created using a combination of Medical Subject Heading
(MeSH) terms and keywords, and were combined using
the Boolean operator OR (Additional file 1, Appendix).
A separate search was performed to identify clinical
trials involving general critical care patients with hetero-
geneous diagnostic categories that were cared for in
multi-system ICUs. Four published meta-analyses were
used to identify relevant manuscripts [50-53], and the
search strategy from one of these was repeated from
March 2008 to November 2011 [51]. The manuscripts of
retrieved studies were reviewed to determine if separate
results were reported specifically for neurocritical care
patients. We also searched the references of included
RCTs and previous systematic reviews relating to inten-
sive insulin therapy.
Study selection
Article selection was performed in two sequential steps.
First, one investigator (AHK) screened the title, abstract
and keywords of all records retrieved using the search
strategy. This stage was intended to be inclusive, and
identified all RCTs involving hospitalized patients that
compared at least two regimens of insulin administration
or glycemic control. Second, the resultant, shorter list
was reviewed independently and in duplicate by two
investigators (AHK, and DJR).
Studies were considered eligible based on the following
inclusion criteria: (1) study design (RCTs only); (2) target
population (adults with at least one of the following con-
ditions: TBI, SAH, ICH, ischemic stroke, anoxic injury,
spinal cord injury or CNS infection); (3) intervention
(comparing an intensive glycemic control protocol with a
conventional (less tight) strategy); and (4) outcome (doc-
umentation of at least one of the primary or secondary
outcomes (see below) in the target population).
Studies were excluded if other aspects of care, besides
glycemic control, differed between groups. Thus, RCTs
assessing the efficacy of glucose-potassium-insulin (GKI)
regimens were not eligible, but were included in a
planned sensitivity analysis. For RCTs involving mixed
populations, but not presenting separate data for neuro-
critical care patients, we included the pooled results only
if >75% of patients had a neurocritical care diagnosis.
Studies consisting largely of non-emergent, perioperative
neurosurgical patients were excluded, since these patients
did not have an acute neurological injury.
Data abstraction and assessment for risk of bias
Independently and in duplicate, two investigators (AHK,
and DJR) abstracted data in an unblinded fashion, using
a standardized form [58]. A translator was consulted to
assist with papers published in a foreign language. Risk
of bias among included RCTs was assessed using the
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following criteria: adequacy of allocation concealment,
blinding of subjects and clinicians to treatment groups,
blinding during outcome adjudication (for studies report-
ing neurological outcomes in addition to mortality), use
of an intention-to-treat analysis, loss to follow-up, and
baseline differences in important prognostic variables. In
each case, we also assigned a Jadad score, which grades
studies’ descriptions of randomization (two points),
blinding (two points) and attrition information (one
point) [59]. Studies with an appropriate randomization
strategy that prevented investigators or clinicians from
predicting subsequent treatment allocation were consid-
ered to have adequate concealment [60]. For subsequent
analyses, we categorized studies as having a relatively
lower risk of bias if the Jadad score was >3 and there was
adequate concealment of allocation. For studies reporting
neurological outcomes, we also required outcome adjudi-
cation to have been performed in a blinded fashion.
Primary outcomes included: (1) 6-month mortality; if
this was not specifically presented, we used the available
time frame closest to 6 months, and (2) poor neurological
recovery, as defined in individual studies. If a full range of
outcomes was presented, we considered a Glasgow Out-
come Scale (GOS) score of 1 to 3 (death, vegetative state
or severe disability), a modified Rankin Scale (mRS) score
of 4 to 6 (moderately severe disability, severe disability,
death) or a cerebral performance category (CPC) of 3 to 5
(severe disability, coma or vegetative state, death) to repre-
sent poor outcomes.
Secondary outcomes, in each case using the definitions
provided within individual studies, included the following:
(1) hypoglycemia (if several definitions were provided, we
utilized the threshold closest to 60 mg/dl); (2) nosocomial
pneumonia; (3) other nosocomial infections.
Data synthesis
Studies were pooled using Comprehensive Meta-Analysis
(version 2.0, Biostat Inc., Englewood, NJ, USA). The risk
ratio was chosen as the summary measure of association.
Random effects models were used to pool risk ratios across
studies and secondary analyses were performed using fixed
effects models. Statistical heterogeneity was assessed with
the I2 statistic and Q-test (with a P-value < 0.10 considered
significant) [61].
Potential reasons for variability in study results were
anticipated in advance, and explored using pre-planned
random effects meta-regression, in which patients were
pooled a priori according to the following factors: glyce-
mic targets in the control group (defined as loose if insulin
was only initiated for glucose concentrations >200 mg/dl,
and moderate if insulin was initiated for lower glucose
concentrations); incidence of hypoglycemia (studies were
dichotomized based on the median incidence, and the two
groups were then compared); diagnosis (subgroups of
studies involving patients with TBI or stroke were assessed
separately); risk of bias (higher vs. lower, as defined above);
and duration of intensive glycemic control (> 72 hours vs.
<72 hours). We also planned sensitivity analyses with




Selection of studies is shown in Figure 1. Our initial search
strategy identified 3,040 references. Of these, 90 involved a
comparison of two insulin or glycemic control strategies
in acute care patients. Another 22 papers, published prior
to March 2008, were identified through previous meta-
analyses of general critical care patients [50-53]. After
removal of 10 duplicates, a list of 102 studies was reviewed
in full during the second stage of article selection. Of
these, 78 were excluded, leaving a total of 23 RCTs specifi-
cally assessing neurocritical care patients.
Of the 23 trials, one study involving perioperative neu-
rosurgical patients was excluded because some of the
data had already previously been published in two papers
that were included in the meta-analysis. Moreover, the
remaining patients primarily had brain tumors, which
were treated with semi-elective surgery [62-64]. However,
because this was a relatively large study, and the appro-
priateness of excluding elective neurosurgical patients is
somewhat debatable, these results were incorporated into
a secondary sensitivity analysis, from which the redun-
dant data from the two other trials were removed [63,64].
Three RCTs involving patients with ischemic stroke used
GKI regimens rather than only intensive insulin as their
experimental treatment [65-67]. Another trial used an
insulin-saline-potassium-magnesium infusion [68]. These
four studies were excluded from the primary analysis, but
their results were incorporated into a secondary analysis.
Two additional RCTs were identified, but did not report
any of our primary or secondary outcomes in the manu-
script [69,70]. Thus, 16 studies, involving 1,248 patients
(654 treated with intensive vs. 594 with conventional gly-
cemic control), were retained for the determination of
primary pooled outcomes [47,63,64,71-83].
Characteristics of included studies
The target glucose concentration among patients treated
with intensive insulin therapy was most often 80 to 110
mg/dl (4.4 to 6.1 mmol/L), but did vary slightly across
RCTs, ranging from 70 to 150 mg/dl (3.9 to 8.3 mmol/L).
Glucose goals were more variable in the conventional
treatment groups. In the most extreme case, insulin ther-
apy was only initiated when glucose levels exceeded 300
mg/dl (16.7 mmol/L), which was, at the time, consistent
with AHA Guidelines for the management of ischemic
stroke [76]. At the opposite extreme, one study had a
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conventional glucose target of 110 to 144 mg/dl (6.1 to
8.0 mmol/L) [77]. In most cases, insulin was only
initiated in control patients when glucose levels exceeded
180 to 200 mg/dl. The duration of treatment varied from
as short as 24 hours to the entire duration of the ICU
admission. Definitions of hypoglycemia ranged from less
than 40 to 80 mg/dl (2.2 to 4.4 mmol/L). The frequency
of glucose monitoring for patients receiving intravenous
(IV) insulin ranged from every 1 to 4 hours. Neurological
outcomes were generally reported using the mRS, GOS
or extended GOS. Relatively little information was pro-
vided on the provision of nutrition; in most cases tube
feeding appeared to have been initiated as soon as possi-
ble to patients who could not eat (Table 1).
The risk of bias varied across studies. In no study were
clinicians blinded to glucose levels. For this reason, the
Jadad score was never > 3. Most studies used an inten-
tion-to-treat analysis and loss to follow-up was relatively
uncommon. Baseline characteristics among patients in
the two groups were largely similar. Individuals adjudi-
cating neurological outcomes were not always blinded
with respect to the treatment group (Table 2).
Effect of intensive glycemic control on mortality and poor
neurological outcomes
There was no statistically significant difference in mortal-
ity between patients treated with intensive (26%) versus
conventional glycemic targets (27%) (relative risk, RR
0.99, 95% CI 0.83 to 1.17, P = 0.89) (Figure 2). There was
little heterogeneity in study results (Q = 8.7, P = 0.89;
I2 = 0%). Findings were consistent in five RCTs involving
patients with TBI (RR 0.99, 95% CI 0.79 to 1.22,
P = 0.89), six RCTs of patients with ischemic stroke (RR
1.10, 95% CI 0.57 to 2.12, P = 0.78), and nine RCTs of
patients with any type of stroke (ischemic or hemorrha-
gic; RR 0.91, 95% CI 0.61 to 1.34, P = 0.63).
In 13 RCTs reporting neurological recovery in 1,023
randomized patients, intensive glycemic control resulted
in a lower risk of poor neurological outcomes (58% vs.
68%; RR 0.91, 95% CI 0.84 to 1.00, P = 0.04) (Figure 3).
There was no significant heterogeneity (Q = 9.6, P= 0.65;
I2 = 0%). A comparable trend was observed in four RCTs
involving 449 patients with TBI (RR 0.91, 95% CI 0.80 to
1.02, P = 0.11) and in eight RCTs involving 457 patients
with either ischemic or hemorrhagic stroke (RR 0.90, 95%
CI 0.77 to 1.05, P = 0.19). Among 241 patients specifically
with ischemic stroke, intensive insulin had no clear effect
(RR 0.97, 0.83 to 1.14, P = 0.71).
Effect of intensive glycemic control on secondary
outcomes
Thirteen trials, involving 967 patients, reported the inci-
dence of hypoglycemia. The proportion of patients trea-
ted with intensive insulin who developed hypoglycemia
varied greatly between studies, ranging from 3 to 100%,
with a median value of 18 to 33%. Although definitions
varied, the incidence of hypoglycemia was markedly
greater among patients treated with intensive insulin
Figure 1 Selection of randomized controlled trials comparing intensive and conventional glycemic control protocols in neurocritical
care patients.
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protocols (30% vs. 14%; RR 3.10, 95% CI 1.54 to 6.23,
P = 0.002) (Figure 4). However, there was a large degree
of heterogeneity between studies (Q = 47.9, P < 0.0001,
I2 = 75%).
Six RCTs reported the incidence of pneumonia. Inten-
sive glycemic control did not have any protective effect
(RR 1.04, 95% CI 0.82 to 1.32, P = 0.73). Mild to moderate
heterogeneity between studies was observed (Q = 6.0, P =
0.31, I2 = 17%). Other nosocomial infections were infre-
quently reported, such that we did not pool the results.
Meta-regression & sensitivity analyses
Results of subgroup analysis and meta-regression are
shown in Table 3. Of the 13 studies reporting the occur-
rence of neurological outcomes, eight used a control
group where glycemic control could be considered,
according to our a priori definition, to have been very
loose, with insulin administered only if glucose was >200
mg/dl (11.1 mmol/L). Five studies used a design where
even the control group received insulin to maintain glu-
cose levels within a relatively narrow range, with a thresh-
old for insulin administration of 144 to 180 mg/dl (8.0 to
10.0 mmol/L). An improvement in outcomes was only
observed in the subgroup of studies where control group
glucose levels were allowed to be relatively high (RR 0.88,
95% CI 0.79 to 0.98, P = 0.02), but not in those where
there was a less extreme difference (RR 0.99, 95% CI 0.85
to 1.14, P = 0.84). The difference between these two cate-
gories of studies was statistically significant (P = 0.04).
As per our a priori plan, studies were dichotomized
into those having a high (33 to 100%) or a low incidence
(3 to 18%) of hypoglycemia. A non-significant increment
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in mortality was seen in studies where the incidence of
hypoglycemia was high (RR 1.17, 95% CI 0.78 to 1.76, P
= 0.44). However, this result did not differ statistically
when compared with studies where the incidence of
hypoglycemia was low.
Twelve studies assessed the efficacy of intensive insu-
lin administered for more than 72 hours. In four studies,
intensive insulin was used more briefly, for time inter-
vals ranging from 24 to 72 hours. No differences in
mortality were observed based on the duration of time
that intensive insulin was administered. In 11 of the 12
studies using more prolonged regimens of intensive
insulin, neurological outcomes were reported and there
was a trend towards an improvement with intensive
therapy (RR 0.92, 95% 0.84 to 1.01, P = 0.07).
Inclusion of the trial that involved postoperative neuro-
surgical patients (and exclusion of patients for whom
there were redundant data) had little impact on the results
[62-64]. On combining the studies assessing the impact of
GKI or insulin-saline-potassium-magnesium infusions in
ischemic stroke patients, there was no improvement in
mortality (reported in three studies; RR 1.08, 95% CI 0.89
to 1.32, P = 0.43) or neurological recovery (reported in
three studies; RR 1.02, 95% CI 0.94 to 1.10, P = 0.63).
When these four RCTs were combined with all other
RCTs, the improvement in functional outcomes associated
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with intensive glycemic control was no longer present
(RR 0.95, 95% CI 0.89 to 1.01, P = 0.11).
Five studies deferred nutritional supplementation for 24
to 48 hours, of which three explicitly mentioned providing
intravenous glucose during this time (Table 1). No
difference in mortality or unfavourable outcomes was
observed in comparison to RCTs where enteral nutrition
was not delayed. Three RCTs explicitly mentioned provid-
ing intravenous glucose supplementation to patients who
were not receiving any other nutrition; in contrast to most
Figure 2 Impact of intensive glycemic control on mortality in neurocritical care patients.
Figure 3 Impact of intensive glycemic control on poor functional recovery in neurocritical care patients.
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other studies, intensive insulin did not significantly
increase the incidence of hypoglycemia in these trials (RR
1.64, 0.56 to 4.80, P = 0.37) [71,79,81].
We also assessed outcomes of studies based on the
definition of hypoglycemia that was used. Eight RCTs
defined hypoglycemia using a relatively high threshold
of glucose ≤ 60 to 80 mg/dl (3.3 to 4.4 mmol/L) and six
studies used a low threshold of glucose ≤ 40 to 55 mg/
dl (2.2 to 3.1 mmol/Ll). There were no differences in
mortality, neurological recovery or the incidence of
hypoglycemia based on these thresholds.
Publication bias
Visual inspection of a funnel plot revealed relative sym-
metry, arguing against the presence of publication bias
(Figure 5). Similarly, there was no evidence of publica-
tion bias using Egger’s test (intercept 0.17, 95% CI -0.52
to 0.86 P = 0.60).
Discussion
Our results provide the most contemporary and compre-
hensive overview of RCTs involving different glycemic
control strategies in neurocritical care patients. Previous
quantitative systematic reviews have been published
[54,55], but they did not include multiple relevant publi-
cations [47,72-78,83], they were based in part on redun-
dant data [62-64], and they did not perform stratified
analyses and meta-regression in order to explain hetero-
geneity in RCT results.
Our findings suggest that intensive glycemic control
does not reduce mortality among neurocritical care
patients. This observation is consistent with the results of
recent large, multi-center RCTs performed in critically ill
patients with more heterogeneous, and not necessarily
neurological, diagnostic categories [47-53].
In contrast, we did observe intensive glycemic control
to reduce the occurrence of poor neurological outcomes.
This finding was largely limited to the subgroup of stu-
dies where target glucose concentrations in the control
group were very loose (insulin initiated only when glu-
cose concentration exceeded 200 mg/dl). A benefit was
not observed when intensive treatment was compared
with more intermediate glycemic targets (110 to 180 mg/
dl). This observation suggests that some of the benefit
from intensive insulin may instead have been related to
harm attributable to loose glucose control. Thus, glucose
Figure 4 Impact of intensive glycemic control on incidence of hypoglycemia in neurocritical care patients.
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Table 3 Subgroup analysis and meta-regression of studies assessing the efficacy of intensive glycemic control in
neurocritical care patients














Very loose 10 0.98 (0.80-1.20) 8 0.88 (0.79-0.98)
Moderate 6 1.00 (0.72-1.39) 0.89 5 0.99 (0.85-1.14) 0.04
Hypoglycemia†
Uncommon 7 1.00 (0.86-1.24) 5 0.94 (0.84-1.06)
Common 6 1.17 (0.78-1.76) 0.72 6 0.94 (0.81-1.08) 0.94
Duration of tight
control
> 72 hours 12 0.99 (0.83-1.18) 11 0.92 (0.84-1.01)
<72 hours 4 0.97 (0.56-1.67) 0.37 2 0.81 (0.57-1.15) 0.04
Risk of bias
Higher 11 1.03 (0.86-1.24) 10 0.94 (0.85-1.04)




6 1.07 (0.73-1.57) 5 0.93 (0.80-1.08)
Deferred > 24
hours
5 1.01 (0.81-1.26) 0.82 4 0.90 (0.79-1.03) 0.79
Definition
Hypoglycemia 8 0.94 (0.67-1.31) 8 0.88 (0.77-1.00)
56-80 mg/dl
55 mg/dl or below
6 1.01 (0.82-1.23) 0.72 4 0.91 (0.79-1.03) 0.72
† As per a priori plan, patients were dichotomized based on the median prevalence of hypoglycemia across studies; common, hypoglycemia occurred in 33-100%
of patients; uncommon, hypoglycemia occurred in 3 to 18% of patients.
Figure 5 Funnel plot showing standard error of studies assessing efficacy of intensive glycemic control in neurocritical care patients
in relation to log of calculated risk ratio.
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concentrations in excess of 180 mg/dl should be avoided
in neurocritical care patients. This finding is consistent
with a large number of animal experiments and human
observational studies.
We found that the incidence of hypoglycemia was
markedly increased by intensive insulin therapy. How-
ever, the rate of hypoglycemia varied greatly across
RCTs. Patients treated with intensive treatment had
somewhat higher mortality in studies where the inci-
dence of hypoglycemia was high (>33%), although this
result was not statistically significant. Hypoglycemia has
been shown to be a strong predictor of mortality in cri-
tically ill patients [47,84]. In brain-injured patients,
microdialysis studies have demonstrated that reductions
in serum glucose concentration may produce profound
neuroglycopenia, which in turn may contribute to meta-
bolic distress and secondary brain injury [43,85-88].
Hypoglycemia may also help explain why the introduc-
tion of an intensive insulin protocol has been associated
with worse outcomes at some centers [89].
One of the proposed complications of hyperglycemia is
an increased vulnerability to nosocomial infections. Only
a small proportion of studies involving neurocritical care
patients reported infection rates. When the results were
combined, we could not find any impact of glycemic con-
trol on the incidence of hospital-acquired pneumonia.
We did not identify one subgroup of neurocritical care
patients in whom intensive insulin therapy was asso-
ciated either with any particular benefit or harm. The
relationship between tighter glycemic control and
improved neurological recovery was, however, stronger
among patients with TBI, ICH or SAH than it was for
patients with ischemic stroke. This finding is consistent
with the lack of benefit observed in RCTs assessing the
efficacy of GKI infusions, all of which exclusively
involved patients with ischemic stroke [65-67]. Our find-
ings should not necessarily be applied to patients under-
going semi-elective neurosurgical procedures, such as
resection of a brain tumor, since these were not
included in the analysis.
We believe that RCTs are consistent with a U-shaped
relationship between serum glucose concentration and
neurological outcomes [43]. Both hypoglycemia and
extreme hyperglycemia are likely to be harmful. Com-
parable observations have also been made in medical
and surgical critical care patients [90]. The optimal glu-
cose target for neurocritical care patients is likely to fall
between 80 and 180 mg/dl (4.4 and 10.0 mmol/L).
Given that RCTs suggest a relatively high incidence of
hypoglycemia when clinicians attempt to maintain glu-
cose levels between 80 and 110 mg/dl (4.4 to 6.1 mmol/
L), we consider a more conservative approach to be
most appropriate, for example, 110 to 180 mg/dl (6.1 to
10.0 mmol/L).
Some large RCTs involving heterogeneous populations
of critically ill patients have not yet published results for
their subgroup of neurological patients, and were there-
fore excluded from this analysis. Most importantly, the
NICE-SUGAR trial included more than 6,000 critically
ill patients [49]. The GLUCONTROL trial designated
142 of 1,078 patients (13%) as having a neurological
diagnostic category, but did not provide results for this
subgroup [91]. Another trial, involving 1,200 medical
ICU patients, reported hospital mortality among 61
patients with neurologic conditions. Because the specific
disorders were not described, it was unclear if these
patients met our eligibility criteria [46]. We were unable
to obtain this information from the authors. However, a
sensitivity analysis performed with inclusion of these
patients did not change our results (RR 0.99, 0.84 to
1.17, P = 0.90).
There are further limitations to this meta-analysis.
Although there were many similarities to the methodol-
ogy of the included RCTs, there was also some variability.
This variability is especially reflected by the wide range of
hypoglycemia (3 to 100%) among patients randomized to
intensive insulin protocols. Any future RCTs of intensive
insulin should therefore first carefully pilot their protocol
to ensure that hypoglycemia can be minimized. There
was some heterogeneity in the provision and reporting of
nutritional supplementation, which may have influenced
the results. Neurological outcomes reported in this meta-
analysis were relatively crude; it remains possible that
glycemic control could have a greater influence on more
subtle neurocognitive or indices of quality of life. Finally,
although we have clustered various neurocritical care
conditions, there may be significant differences across
disease states, or based on brain-injury severity, that
may influence the pathophysiology and implications of
hyperglycemia.
Conclusions
In summary, a growing number of RCTs, involving
many hundreds of patients, cumulatively demonstrate
that intensive glycemic control does not reduce mortal-
ity in neurocritical care patients. A unique benefit in
certain subgroups cannot be excluded, but no such
trend was observed in our analysis. Very loose glycemic
control with a target of > 180 mg/dl (10 mmol/L)
appears to be harmful and should be avoided. Intensive
control with target glucose of 80 to 110 mg/dl (4.4 to
6.1 mmol/L) greatly increases the risk of hypoglycemia.
Thus, at present, the literature supports targeting more
intermediate glucose levels.
Key messages
• Intensive glycemic control does not appear to
improve mortality in neurocritical care patients.
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• Very loose glycemic control with insulin initiated
only for glucose concentrations >200 mg/dl (11.1
mmol/L) is associated with poor neurological out-
comes in neurocritical care patients, compared with
either intensive insulin therapy with a target glucose
concentration of 80 to 110 mg/dl (4.4 to 6.1 mmol/
L), or more modest glycemic control with a target
glucose concentration of 110 to 180 mg/dl (6.1 to
10.0 mmol/L).
• Intensive glycemic control greatly increases the risk
of hypoglycemia in neurocritical care patients.
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